explore -WSS

explore

author：comprehensive 2025-10-01 12:54:43 - browse：52524

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： RSV injection headlines need to be accurate for good uptake

focus

WSS

New oral drug delivery patch is modeled after octopus tentacles

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Community Health Systems hospitals under DOJ investigation

Alabama frozen embryo ruling has major implications for IVF clinics

WHO recommends second malaria vaccine

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

explore

Virginia high school admissions case could be legal follow

European officials brace for rough respiratory virus season

Malaria cases in Florida and Texas: Here’s what you need to know

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

The cancer drug shortage isn’t new — and neither are the solutions

6 phony surgeries that take placebo to the extreme

Medical leaders decry Supreme Court decision on affirmative action

Flu, Covid vaccination rates decline, new survey data show

Trump demands the U.S. pay no more for drugs than other countries … again

STAT readers on older presidents, polypills, Medicare, and more

hotspot

The biotech scorecard for Q4: 16 stock

Experts study whether long Covid risk adds up with each reinfection

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

WHO recommends second malaria vaccine

Will an HIV vaccine ever be a reality?

IVG is promising — but it won’t replace IVF quite yet

focus

focus

Wikipedia

explore